Liminatus Adjusts InnocsAI Merger to Bolster Pipeline
Published on June 30, 2026, the article says Liminatus Pharma has amended its definitive merger agreement with InnocsAI to expand its oncology cell therapy pipeline. The +24.35% stock move reflects a very positive market reaction to the strategic step, seen as a sign of a stronger clinical portfolio and improved growth outlook for the group.